139 related articles for article (PubMed ID: 1891900)
1. [Gemfibrozil in the treatment of hyperlipoproteinemias].
Monova D; Petrova V; Belovezhdov N
Vutr Boles; 1991; 30(2):56-8. PubMed ID: 1891900
[TBL] [Abstract][Full Text] [Related]
2. [Evaluation of the efficiency of gemfibrozil in treating hyperlipidemia type IIb and IV].
Polakowska M; Broda G; Rywik S; Piotrowski W; Bednarska M; Kuźmińska A; Pytlak A; Chotkowska E
Pol Arch Med Wewn; 1994 Jan; 91(1):9-18. PubMed ID: 8190659
[TBL] [Abstract][Full Text] [Related]
3. [The clinico-biochemical activity and tolerance of the hypolipidemic preparation lipanthyl].
Ol'binskaia LI; Vartanova OA; Aleksandrovskaia TN; Shaldaeva VV
Ter Arkh; 1991; 63(8):61-4. PubMed ID: 1792621
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of ciprofibrate in primary type II and IV hyperlipidemia: the Italian multicenter study.
Cattin L; Da Col PG; Feruglio FS; Finazzo L; Rimondi S; Descovich G; Manzato E; Zambon S; Crepaldi G; Siepi D
Clin Ther; 1990; 12(6):482-8. PubMed ID: 2289217
[TBL] [Abstract][Full Text] [Related]
5. Effect of gemfibrozil on serum lipid levels.
Dahlén G; Gillnäs T; Børresen AL; Berg K; Ericson C
Artery; 1980; 7(3):224-31. PubMed ID: 7008748
[TBL] [Abstract][Full Text] [Related]
6. [Evaluation of the effectiveness of gemfibrozil in primary dyslipoproteinemias. II. Relation between the results of treatment and type of dyslipoproteinemia].
Sznajd J; Malczewska-Malec M; Idzior-Waluś B; Iwanejko J; Nowacki G
Przegl Lek; 1987; 44(12):837-43. PubMed ID: 3330253
[No Abstract] [Full Text] [Related]
7. [Gemfibrozil in the treatment of hyperlipoproteinemia].
Ceska R; Sobra J
Vnitr Lek; 1989 Oct; 35(10):967-71. PubMed ID: 2617883
[TBL] [Abstract][Full Text] [Related]
8. Gemfibrozil therapy in primary type II hyperlipoproteinemia: effects on lipids, lipoproteins and apolipoproteins.
Lupien PJ; Brun D; Gagné C; Moorjani S; Bielman P; Julien P
Can J Cardiol; 1991; 7(1):27-33. PubMed ID: 2025787
[TBL] [Abstract][Full Text] [Related]
9. Changes in serum and lipoprotein lipids, and apolipoprotein B and A-I, in patients with different types of primary hyperlipoproteinaemia treated with gemfibrozil.
Sommariva D; Branchi A; Pini C; Scandiani L; Orlandi S; Fasoli A
Int J Clin Pharmacol Res; 1988; 8(5):383-92. PubMed ID: 3068163
[TBL] [Abstract][Full Text] [Related]
10. [Evaluation of the effectiveness of gemfibrozil in primary dyslipoproteinemias. I. Changes in lipid levels after treatment (the "net" reduction)].
Sznajd J; Malczewska-Malec M; Idzior-Waluś B; Jamska B; Nowacki G
Przegl Lek; 1987; 44(12):828-36. PubMed ID: 3330252
[No Abstract] [Full Text] [Related]
11. [Indications for and the therapeutic action of hypolipidemic agents in patients with hyperlipoproteinemias].
Goranov I; Naumova R; Kerekovska M; Balabanski L
Vutr Boles; 1987; 26(1):96-101. PubMed ID: 3590738
[TBL] [Abstract][Full Text] [Related]
12. Lowering effect of fenofibrate (procetofene) on lipoproteins in different types of hyperlipoproteinemias.
Canzler H; Bojanovski D
Artery; 1980; 8(2):171-8. PubMed ID: 7458684
[TBL] [Abstract][Full Text] [Related]
13. Reversible increase of the apo CII/apo CIII-1 ratio in the very low density lipoproteins after procetofen treatment in hypertriglyceridemic patients.
Franceschini G; Sirtori M; Gianfranceschi G; Frosi T; Montanari G; Sirtori CR
Artery; 1985; 12(6):363-81. PubMed ID: 4051756
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation of apoproteins A and B, lipoproteins and plasma lipids during treatment with bezafibrate in various forms of hyperlipoproteinemia].
Saitta A; Bonaiuto M; Lanzafame F; Mileto A; Pernice F; Cinquegrani M; Mazza G; Micali G; Pangallo A; Fodale P
Clin Ter; 1988 Mar; 124(5):373-81. PubMed ID: 2974348
[No Abstract] [Full Text] [Related]
15. Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolemia.
Franceschini G; Sirtori M; Vaccarino V; Gianfranceschi G; Chiesa G; Sirtori CR
J Lab Clin Med; 1989 Sep; 114(3):250-9. PubMed ID: 2504855
[TBL] [Abstract][Full Text] [Related]
16. [Sulfinpyrazone and lipoproteins: absence of effects on serum lipids in hyperlipoproteinemias of types II and IV].
Sommariva D; Scotti L; Baroni L; Beggi P; Fasoli A
Clin Ter; 1980 Mar; 92(6):649-55. PubMed ID: 7460493
[No Abstract] [Full Text] [Related]
17. [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V].
Hutt V; Wechsler JG; Klör HU; Ditschuneit H
Arzneimittelforschung; 1983; 33(5):776-9. PubMed ID: 6683558
[TBL] [Abstract][Full Text] [Related]
18. [Effective long-term treatment of primary hyperlipoproteinemias with bezafibrate].
Schiffl H; Weidmann P; Fragiacomo C; Noseda G; Bachmann C
Schweiz Med Wochenschr; 1985 Jun; 115(26):907-11. PubMed ID: 3927481
[TBL] [Abstract][Full Text] [Related]
19. [Effect of bezafibrate therapy on serum and lipoprotein lipids].
Romics L; Németh Csóka M; Szám I; Pados G; Karádi I; Köszegi G; Kusztos R
Orv Hetil; 1986 Oct; 127(40):2425-8, 2431. PubMed ID: 3537905
[No Abstract] [Full Text] [Related]
20. Treatment of hyperlipoproteinemia, types II and IV, with pirifibrate: one hundred observations.
Bonora V; Calalabuig RJ; Caviola E; Soler J; Pueyo JM; Micaló T; Cano RP
Clin Ther; 1981; 4(3):192-200. PubMed ID: 7030489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
